Next-Gen SERDs in ER+/HER- Breast Cancer Satellite Symposium

The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Treatment with patritumab deruxtecan appears to yield improved responses in patients who have been heavily pretreated for metastatic breast cancer.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.

Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.